SEC Form 4 · accession 0001209191-18-009012
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Azelby
Officer — EVP & Chief Commercial Officer
Period of report
Feb 7, 2018
Accepted (ET)
Feb 9, 2018 · 7:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 7, 2018 | F | 2,700 | $85.49 | D | 93,771 | D | |
| Common Stock | Feb 8, 2018 | M | 834 | $25.29 | A | 94,605 | D | |
| Common Stock | Feb 8, 2018 | M | 2,663 | $20.76 | A | 97,268 | D | |
| Common StockF2 | Feb 8, 2018 | S | 3,497 | $85.77 | D | 93,771 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $25.29 | Feb 8, 2018 | M | 834 | D | — | Nov 7, 2026 | Common Stock | 834 | 30,002 | D |
| Stock Option (Right to Buy)F4 | $20.76 | Feb 8, 2018 | M | 2,663 | D | — | Feb 6, 2027 | Common Stock | 2,663 | 98,545 | D |
Explanation of responses
- F1Shares withheld by the issuer to satisfy tax withholding obligations on the vesting of restricted stock units.
- F2The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.
- F31/48th of the shares subject to the option vested and became exercisable on December 8, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.
- F41/48th of the shares subject to the option vested and became exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.